TPST
Income statement / Annual
Last year (2023), Tempest Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Tempest Therapeutics, Inc.'s net income was -$29.49 M.
See Tempest Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$295,000.00
|
$653,000.00
|
$277,000.00
|
$9.74 M
|
| Cost of Revenue |
$381,000.00 |
$1.81 M |
$1.27 M |
$815,000.00 |
$1.05 M |
$32,000.00 |
$28,000.00 |
$5.40 M |
$2.25 M |
$0.00 |
| Gross Profit |
-$381,000.00 |
-$1.81 M |
-$1.27 M |
-$815,000.00 |
-$1.05 M |
-$32,000.00 |
$267,000.00 |
-$4.75 M |
-$1.97 M |
$9.74 M |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0.91 |
-7.27 |
-7.12 |
1 |
| Research and Development
Expenses |
$17.50 M
|
$22.53 M
|
$17.17 M
|
$14.39 M
|
$27.84 M
|
$14.43 M
|
$14.53 M
|
$21.64 M
|
$18.43 M
|
$21.78 M
|
| General & Administrative
Expenses |
$11.66 M
|
$12.11 M
|
$9.82 M
|
$4.91 M
|
$5.51 M
|
$12.45 M
|
$27.74 M
|
$49.22 M
|
$51.59 M
|
$26.15 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$16.50 M
|
-$3.79 M
|
-$21.82 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$11.66 M
|
$12.11 M
|
$9.82 M
|
$4.91 M
|
$16.50 M
|
$8.66 M
|
$5.93 M
|
$49.22 M
|
$51.59 M
|
$26.15 M
|
| Other Expenses |
$0.00 |
$549,000.00 |
-$34,000.00 |
$0.00 |
$0.00 |
$0.00 |
$4.03 M |
$5.40 M |
$0.00 |
$0.00 |
| Operating Expenses |
$29.16 M |
$34.64 M |
$26.99 M |
$19.30 M |
$44.35 M |
$23.08 M |
$20.45 M |
$70.86 M |
$70.03 M |
$47.93 M |
| Cost And Expenses |
$29.16 M |
$34.64 M |
$26.99 M |
$19.30 M |
$45.40 M |
$23.12 M |
$20.48 M |
$76.27 M |
$72.28 M |
$47.93 M |
| Interest Income |
$1.12 M |
$549,000.00 |
$1,282.00 |
$90,000.00 |
$264,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$1.45 M |
$1.62 M |
$1.28 M |
$0.00 |
$0.00 |
$134,000.00 |
$0.00 |
$659,000.00 |
$436,000.00 |
$0.00 |
| Depreciation &
Amortization |
$381,000.00
|
$1.81 M
|
$1.27 M
|
$815,000.00
|
$1.05 M
|
$32,000.00
|
$28,000.00
|
$2.24 M
|
$1.29 M
|
$450,000.00
|
| EBITDA |
-$28.78 M
|
-$32.28 M
|
-$25.72 M
|
-$18.39 M
|
-$43.52 M
|
-$27.01 M
|
-$84.27 M
|
-$79.82 M
|
-$71.86 M
|
-$49.07 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
-69.34 |
-112.36 |
-255.28 |
-5.04 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
-69.43
|
-115.79
|
-259.92
|
-4.92
|
| Total Other
Income/Expenses Net |
-$334,000.00
|
-$1.07 M
|
-$1.32 M
|
$90,000.00
|
-$21.19 M
|
-$4.06 M
|
-$64.10 M
|
-$1.05 M
|
-$1.15 M
|
-$1.59 M
|
| Income Before Tax |
-$29.49 M |
-$35.71 M |
-$28.30 M |
-$19.21 M |
-$44.57 M |
-$27.18 M |
-$84.59 M |
-$82.06 M |
-$73.14 M |
-$49.52 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
-286.73
|
-125.66
|
-264.06
|
-5.09
|
| Income Tax Expense |
$0.00 |
$1.07 M |
$1.25 M |
-$90,000.00 |
$1,000.00 |
-$169,000.00 |
$67,000.00 |
$201,000.00 |
$75,000.00 |
-$1.59 M |
| Net Income |
-$29.49 M |
-$36.78 M |
-$29.55 M |
-$19.12 M |
-$44.57 M |
-$27.19 M |
-$84.58 M |
-$82.26 M |
-$73.22 M |
-$49.52 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
-286.71 |
-125.97 |
-264.33 |
-5.09 |
| EPS |
-1.91 |
-3.18 |
-7.8 |
-612.56 |
-48.77 |
-263.65 |
-72406.33 |
-575.73 |
-608.25 |
-491.98 |
| EPS Diluted |
-1.91 |
-3.18 |
-7.8 |
-612.56 |
-48.77 |
-263.65 |
-72406.33 |
-575.73 |
-608.25 |
-491.98 |
| Weighted Average Shares
Out |
$15.42 M
|
$11.55 M
|
$3.79 M
|
$31,210.00
|
$913,782.00
|
$103,136.00
|
$1,168.10
|
$142,879.00
|
$120,377.00
|
$100,654.00
|
| Weighted Average Shares
Out Diluted |
$15.42 M
|
$11.55 M
|
$3.79 M
|
$31,210.00
|
$913,782.00
|
$103,136.00
|
$1,168.10
|
$142,879.00
|
$120,377.00
|
$100,654.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
